Edition:
United Kingdom

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

67.03USD
24 Sep 2018
Change (% chg)

$0.53 (+0.80%)
Prev Close
$66.50
Open
$66.45
Day's High
$67.40
Day's Low
$66.36
Volume
16,669
Avg. Vol
35,573
52-wk High
$76.98
52-wk Low
$31.56

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Q2 Loss Per Share EUR 0.55
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - Ascendis Pharma A/S ::REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE EUR 0.55.Q2 EARNINGS PER SHARE VIEW EUR -0.90 -- THOMSON REUTERS I/B/E/S.  Full Article

Ascendis Pharma Files For Potential Mixed Shelf Offering, Size Not Disclosed - SEC Filing
Wednesday, 30 May 2018 

May 30 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA A/S FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Ascendis Pharma Announces Dosing Of First Subjects In Phase 1 Trial Of Transcon CNP

* ASCENDIS PHARMA A/S ANNOUNCES DOSING OF FIRST SUBJECTS IN PHASE 1 TRIAL OF TRANSCON CNP